SVB Leerink starts Aclaris Therapeutics at OP; PT $13

SVB Leerink initiated coverage of Aclaris Therapeutics (NASDAQ:ACRS) with an “outperform” rating and $13 price target. The stock closed at $6.34 on May 3.

Aclaris is transitioning from a specialty play in dermatology to a play that is a bit more substantive in immuno-dermatology, writes analyst Dr. Pasha Sarrat.

Through licensing and acquisitions, Aclaris has put together a portfolio of Janus kinase inhibitors to pursue treatment in niche indications, including various autoimmune alopecias and vitiligo.

“We see these indications having significant unmet need but also see a crowded pipeline, with big players trying to capture its value,” Dr. Sarrat said. “2019 is a data heavy year for Aclaris’ portfolio, which will catalyze an inflection, if patient outcomes are compelling.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.